



## Aldeyra Therapeutics Announces Promotion of David McMullin to Position of Chief Commercial Officer

January 3, 2019

LEXINGTON, Mass., Jan. 3, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that David McMullin has been promoted to the position of Chief Commercial Officer, effective immediately. In his new role, Mr. McMullin will oversee Aldeyra's strategic initiatives, commercial planning activities, marketing, and commercial infrastructure development.

"Based on his deep understanding of orphan and large pharmaceutical markets, Dave is well positioned to lead our commercial development efforts," commented Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. "I look forward to working closely with Dave as he prepares for commercialization of our late-stage clinical pipeline."

Mr. McMullin joined Aldeyra in May 2018 as Senior Vice President and Head of Corporate Development and Strategy, and has more than 20 years of experience leading commercialization, business development, and strategic planning operations in the biopharmaceutical industry. Prior to joining Aldeyra, Mr. McMullin was Group Vice President and Head of U.S. Internal Medicine at Shire plc, a \$1.4 billion commercial business unit. Mr. McMullin also ran Global Commercial Operations at Shire Plc and was an in-line Committee member, responsible for commercial performance and execution worldwide. Prior to his work at Shire, Mr. McMullin held roles of increasing responsibility in corporate strategy, marketing, sales, and operations at Novartis International AG. Mr. McMullin received an M.B.A. from Harvard Business School, and a Bachelor of Science degree from Brigham Young University.

### **About Aldeyra Therapeutics**

Aldeyra Therapeutics is developing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for autoimmune disease, post-transplant lymphoproliferative disease, retinal inflammation, metabolic disease, and cancer. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.

### **Safe Harbor Statement**

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Aldeyra's strategy, future operations, future, prospects, plans, and objectives and Aldeyra's plans and expectations for its product candidates, including plans to commercialize its late-stage clinical pipeline. Aldeyra intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "anticipate," "project," "target," "design," "estimate," "predict," "potential," "aim," "plan" or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Aldeyra is at an early stage of development and may not ever have any products that generate significant revenue. All of Aldeyra's development timelines may be subject to adjustment depending on recruitment rate, regulatory review, preclinical and clinical results, and other factors that could delay the initiation or completion of clinical trials. Important factors that could cause actual results to differ materially from those reflected in Aldeyra's forward-looking statements include, among others, the timing of enrollment, commencement and completion of Aldeyra's clinical trials, the timing and success of preclinical studies and clinical trials conducted by Aldeyra and its development partners; updated or refined data based on Aldeyra's continuing review and quality control analysis of clinical data, Aldeyra's ability to design clinical trials with protocols and endpoints acceptable to applicable regulatory authorities, the ability to obtain and maintain regulatory approval of Aldeyra's product candidates, and the labeling for any approved products; the scope, progress, expansion, and costs of developing and commercializing Aldeyra's product candidates; the size and growth of the potential markets and pricing for Aldeyra's product candidates and the ability to serve those markets; Aldeyra's expectations regarding Aldeyra's expenses and revenue, the sufficiency or use of Aldeyra's cash resources and needs for additional financing; the rate and degree of market acceptance of any of Aldeyra's product candidates; Aldeyra's expectations regarding competition; Aldeyra's anticipated growth strategies; Aldeyra's ability to attract or retain key personnel; Aldeyra's ability to establish and maintain development partnerships; Aldeyra's expectations regarding federal, state and foreign regulatory requirements; regulatory developments in the United States and foreign countries; Aldeyra's ability to obtain and maintain intellectual property protection for its product candidates; the anticipated trends and challenges in Aldeyra's business and the market in which it operates; and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Aldeyra's Annual Report on Form 10-K for the year ended December 31, 2017 and Aldeyra's Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, both of which are on file with the Securities and Exchange Commission (SEC) and available on the SEC's website at [www.sec.gov](http://www.sec.gov). Additional factors may be described in those sections of Aldeyra's Annual Report on Form 10-K for the year ended December 31, 2018, expected to be filed with the SEC in the first quarter of 2019.

In addition to the risks described above and in Aldeyra's other filings with the SEC, other unknown or unpredictable factors also could affect Aldeyra's results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Aldeyra undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

### **Corporate Contact:**

David McMullin  
Aldeyra Therapeutics, Inc.

Tel: 781-761-4904 ext. 218  
[dcmullin@aldeyra.com](mailto:dcmullin@aldeyra.com)

**Investor Contact:**

Chris Brinzey  
Westwicke Partners  
Tel: 339-970-2843  
[Chris.brinzey@westwicke.com](mailto:Chris.brinzey@westwicke.com)

 View original content: <http://www.prnewswire.com/news-releases/aldeyra-therapeutics-announces-promotion-of-david-mcmullin-to-position-of-chief-commercial-officer-300772372.html>

SOURCE Aldeyra Therapeutics, Inc.